Everything below concerns gastric juice protein. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
| Property | Value | Notes |
|---|---|---|
| Study species | Rodents, mainly rats | Most reports use surgically induced injury models |
| Typical administration route | Subcutaneous or intraperitoneal injection | Routes differ between reports, which complicates comparison |
| Human trial evidence | Limited, small-scale reports | No large randomized trial in indexed journals |
| Reported outcome categories | Mucosal healing, tendon repair, vascular recovery | Endpoints are not standardized across studies |
| Mechanism status | Not established | Proposed pathways lack direct confirmation |
Proposed mechanisms in the literature involve the nitric oxide system, vascular endothelial growth factor signaling, and epidermal growth factor receptor pathways. Some studies report changes in blood vessel formation or in inflammatory mediators, while others describe interactions with nervous tissue. Much of this evidence rests on molecular markers in cultured cells or animal models. Whether the same pathways operate the same way in humans has not been established. Authors therefore tend to describe mechanisms as hypothetical rather than settled.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
The Type 1 RNA evolved to be catalytically inactive, but complexing with the Type 5 RNA boosted its polymerization ability and enabled intermolecular interactions with the RNA template substrate obviating the need to tether the template directly to the RNA sequence of the RPR, which was a limitation of earlier studies. Not only did t5(+1) not need tethering to the template, but a primer was not needed either as t5(+1) had the ability to polymerize a template in both 3' → 5' and 5' 3 → 3' directions. A highly evolved RNA polymerase ribozyme was able to function as a reverse transcriptase, that is, it can synthesize a DNA copy using an RNA template. Such an activity is considered to have been crucial for the transition from RNA to DNA genomes during the early history of life on earth. Reverse transcription capability could have arisen as a secondary function of an early RNA-dependent RNA polymerase ribozyme. An RNA sequence that folds into a ribozyme is capable of invading duplexed RNA, rearranging into an open holopolymerase complex, and then searching for a specific RNA promoter sequence, and upon recognition rearrange again into a processive form that polymerizes a complementary strand of the sequence. This ribozyme is capable of extending duplexed RNA by up to 107 nucleotides, and does so without needing to tether the sequence being polymerized. A short 20-nucleotide RNA variant ribozyme was identified that self-reproduces via template directed ligation of two 10 nucleotide oligomers.
=== Analogues === 3,4-DMA is an analogue of the catecholamine neurotransmitters dopamine (3,4-dihydroxyphenethylamine), norepinephrine (noradrenaline; 3,4,β-trihydroxyphenethylamine), and epinephrine (adrenaline; 3,4,β-trihydroxy-N-methylphenethylamine). It is also an analogue of psychedelics and entactogens like mescaline (3,4,5-trimethoxyphenethylamine), 3,4,5-trimethoxyamphetamine (TMA), and 3,4-methylenedioxyamphetamine (MDA), among others. Positional isomers of 3,4-DMA include 2,3-dimethoxyamphetamine (2,3-DMA), 2,4-dimethoxyamphetamine (2,4-DMA), 2,5-dimethoxyamphetamine (2,5-DMA), 2,6-dimethoxyamphetamine (2,6-DMA), and 3,5-dimethoxyamphetamine (3,5-DMA). Other analogues of 3,4-DMA include 3,4-dimethoxyphenethylamine (DMPEA), 3-methoxyamphetamine (3-MA), 4-methoxyamphetamine (PMA), 3,4-ethylenedioxyamphetamine (EDMA), and 3,4-dihydroxyamphetamine (DHA; α-methyldopamine), among others.
Around 90% of the protein structures available in the Protein Data Bank have been determined by X-ray crystallography. This method allows one to measure the three-dimensional (3-D) density distribution of electrons in the protein, in the crystallized state, and thereby infer the 3-D coordinates of all the atoms to be determined to a certain resolution. Roughly 7% of the known protein structures have been obtained by nuclear magnetic resonance (NMR) techniques. For larger protein complexes, cryo-electron microscopy can determine protein structures. The resolution is typically lower than that of X-ray crystallography, or NMR, but the maximum resolution is steadily increasing. This technique is still a particularly valuable for very large protein complexes such as virus coat proteins and amyloid fibers. General secondary structure composition can be determined via circular dichroism. Vibrational spectroscopy can also be used to characterize the conformation of peptides, polypeptides, and proteins. Two-dimensional infrared spectroscopy has become a valuable method to investigate the structures of flexible peptides and proteins that cannot be studied with other methods. A more qualitative picture of protein structure is often obtained by proteolysis, which is also useful to screen for more crystallizable protein samples. Novel implementations of this approach, including fast parallel proteolysis (FASTpp), can probe the structured fraction and its stability without the need for purification.
Tourism is a significant contributor to the Romanian economy, generating around 5% of GDP. The number of tourists has been rising steadily, reaching 9.33 million foreign tourists in 2016, according to the Worldbank. Tourism in Romania attracted €400 million in investments in 2005. More than 60% of the foreign visitors in 2007 were from other EU countries. The popular summer attractions of Mamaia and other Black Sea Resorts attracted 1.3 million tourists in 2009. Among Romania's spa towns and resorts are Buziaș, Băile Călacea, Moneasa, Băile Lipova, Călimănești, Amara, and Geoagiu-Băi. At the same time, seaside resorts such as Eforie, Mangalia, Saturn, Venus, Neptun, Olimp, and Mamaia (sometimes also called the Romanian Riviera) are among the main tourist attractions during the summer. Most popular skiing resorts are along the Valea Prahovei, Muntele Mic, Semenic, Straja and Poiana Brașov. Wine tourism is represented by areas such as Recaș, Silagiu, Odobești, Drăgășani, and Podgoria Aradului. Castles, fortifications, or strongholds as well as preserved medieval Transylvanian cities or towns such as Timișoara, Cluj-Napoca, Sibiu, Brașov, Alba Iulia, Baia Mare, Bistrița, Mediaș, Cisnădie, Sebeș, or Sighișoara also attract a large number of tourists. Bran Castle, near Brașov, is one of the most famous attractions in Romania, drawing hundreds of thousands of tourists every year as it is often (falsely) advertised as being Dracula's Castle. Other attractions include the Danube Delta or the Sculptural Ensemble of Constantin Brâncuși at Târgu Jiu.
SISCAPA’s use of proteolytic digestion as a first step eliminates the protein:protein complexes (including complexes of a target protein with auto-antibodies) that cause “interferences” in protein capture assays, including conventional immunoassays (e.g., ELISA assays). Elimination of such autoantibody interferences drove the adoption of SISCAPA as an alternative to immunoassays for clinical measurement of thyroglobulin as a marker of thyroid cancer recurrence in patients who exhibit anti-thyroglobulin autoantibodies. A limitation of the specific peptide capture approach is the requirement for a specially developed antibody against the selected peptide. To date several hundred anti-peptide antibody reagents have been developed for enrichment of tryptic peptides from sample digests, mainly for established clinical biomarkers (,) and cancer research targets, but these do not yet cover a majority of protein targets of interest in non-cancer research or clinical contexts. A variety of MS instrument types have been used for quantitation of the enriched peptides, including most frequently triple quadrupole mass spectrometers implementing the “multiple reaction monitoring” (MRM) method (a format sometimes referred to as “immuno-MRM”), and MALDI-ToF (a format sometimes referred to as iMALDI).
Sources: en.wikipedia.org
==== Metabolic acidosis and potassium ==== The bicarbonate content should ideally be between 17 and 22 mEq/L. Sodium bicarbonate or potassium citrate is administered for buffering, whereby the latter also compensates for any existing potassium deficiency. A diet rich in potassium and magnesium is recommended and is already used in most commercial kidney diets. Potassium gluconate can also be used to compensate for a potassium deficiency, but potassium chloride is usually poorly accepted by cats and often causes gastrointestinal disorders. The restriction of renal excretion in stage IV, ACE inhibitors or aldosterone deficiency due to renin deficiency can also lead to hyperkalemia, which is why potassium levels must be checked regularly and a low-potassium diet may also need to be used.
SR-16435 is a drug which acts as a potent partial agonist at both the μ-opioid receptor and nociceptin receptor. In animal studies it was found to be a potent analgesic, with results suggestive of reduced development of tolerance and increased activity against neuropathic pain compared to classic μ-selective agonists.
A gonadotropin-releasing hormone antagonist (GnRH antagonist) is a GnRH modulator that blocks the GnRH receptor resulting in an immediate drop in gonadotropin (FSH, LH) secretion. GnRH antagonists are primarily used in IVF treatments to block natural ovulation.
From late 1941 the LRDG co-operated closely with the newly formed Special Air Service (SAS), which also included some Rhodesians. The Rhodesian LRDG patrols transported and supported SAS troops during operations behind Axis lines. The LRDG also maintained a constant "Road Watch" along the Via Balbia on the north coast of Libya, along which almost all Axis road traffic from Tripoli, the main Libyan port, had to travel east. The LRDG set up a watch post about 8 kilometres (5.0 mi) east of the Italian Marble Arch monument, and teams of two men each recorded Axis vehicle and troop movements in shifts throughout the day and night. This information was relayed back to the British commanders in Cairo. Rommel advanced east from January 1942, and won a major victory over the Eighth Army, commanded by Lieutenant-General Neil Ritchie, at the Battle of Gazala in May–June 1942. The Axis soon thereafter captured Tobruk. During the Axis victory at the "Retma Box"—part of the British-devised system whereby isolated, strongly fortified "boxes", each manned by a brigade group, formed the front line—and the subsequent Allied retreat, the Southern Rhodesian Anti-Tank Battery lost five men killed, nine wounded and two missing; 37 were captured. Rommel's advance was stalled in July by the Eighth Army, now headed by General Claude Auchinleck, at the First Battle of El Alamein in western Egypt. Two months later the Rhodesians of the LRDG took part in Operation Bigamy (a.k.a. Operation Snowdrop), an unsuccessful attempt by the SAS and LRDG to raid Benghazi harbour.
Sources: en.wikipedia.org
These frequent long treatments are often done at home while sleeping, but home dialysis is a flexible modality and schedules can be changed day to day, week to week. In general, studies show that both increased treatment length and frequency are clinically beneficial. Hemo-dialysis was one of the most common procedures performed in U.S. hospitals in 2011, occurring in 909,000 stays (a rate of 29 stays per 10,000 population).
"The 1947 incident found Government policies at odds with the whole Arab community, including those who manned the police forces". The 1948 Arab–Israeli War made immigration into Israel very difficult, as the Red Sea and Suez Canal were closed by the Egyptian government. By 1949 and after the declaration of a cease fire, 12,000 Jews from Yemen, Aden and the Protectorate were gathered in camps, from where they were airlifted on average 300 a day to Israel, in Operation Magic Carpet, including 1,200 from Aden. An individual described as "the last Jew to leave the protectorate" arrived in Israel on November 6, 1967, the rapid demise of a Jewish community that dated back as much as 2,000 years and that had dwindled to about 400 people having been precipitated by the oppression they faced.
== Oxidants and reductants == Oxidizing agents are added to flour to help with gluten development. They may or may not also act as bleaching agents. Originally flour was naturally aged through exposure to the atmosphere. Oxidizing agents primarily affect sulfur-containing amino acids, ultimately helping to form disulfide bridges between the gluten molecules. The addition of these agents to flour will create a stronger dough. Dehydroascorbic acid and potassium bromate are oxidants, acting on sulfhydryl groups and disulfide bonds in wheat dough, in particular oxidizing glutathione. Potassium bromate acts more directly or with fewer chemical conversion steps than ascorbic acid. Glutathione increases wheat dough's extensibility, or relaxes it, while oxidizing a dough's glutathione increases elasticity. Common oxidizing agents are:
There was low- to moderate-strength evidence of no benefit for most of the other medications used in RCTs, which included antidepressants (bupropion, mirtazapine, sertraline), antipsychotics (aripiprazole), anticonvulsants (topiramate, baclofen, gabapentin), naltrexone, varenicline, citicoline, ondansetron, prometa, riluzole, atomoxetine, dextroamphetamine, and modafinil.
The frequency of the SNP differed significantly by race, partly explaining observed differences in response to interferon therapy between European-Americans and African-Americans. Unconfirmed results suggested that interferon eye drops may be an effective treatment for people who have herpes simplex virus epithelial keratitis, a type of eye infection. There is no clear evidence to suggest that removing the infected tissue (debridement) followed by interferon drops is an effective treatment approach for these types of eye infections. Unconfirmed results suggested that the combination of interferon and an antiviral agent may speed the healing process compared to antiviral therapy alone. When used in systemic therapy, IFNs are mostly administered by an intramuscular injection. The injection of IFNs in the muscle or under the skin is generally well tolerated. The most frequent adverse effects are flu-like symptoms: increased body temperature, feeling ill, fatigue, headache, muscle pain, convulsion, dizziness, and hair thinning. IFN treatment has been associated with neuropsychiatric adverse effects such as depression, anxiety, irritability, and sleep disturbance. Local injection site reactions, particularly erythema, pain, and induration, are also frequently observed. IFN therapy causes immunosuppression, in particular through neutropenia, and can result in some infections manifesting in unusual ways.
Sources: en.wikipedia.org
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.
Human evidence is sparse and comes from small reports rather than large trials. Sample sizes are generally too small to support firm conclusions. The published record does not contain an independently replicated randomized trial.
Several pathways have been proposed, including effects on nitric oxide signaling and vessel formation. Direct confirmation of a primary molecular target is lacking. Some findings rest on indirect measurements, which leaves the mechanism an open question.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.